Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | SVRA Stock NewsStockTitan·12 hours agoSVRA+2.75%
Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI programPUBT·Jul 15 at 11:52 AMSVRA+2.75%
Savara (SVRA) Stock May Trade At A Premium On Pipeline ExpectationsSimplywall·Jul 8 at 07:18 AMSVRA+2.75%
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?Simplywall·Jun 29 at 02:50 PMSVRA+2.75%
Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?Simplywall·Jun 28 at 11:04 AMSVRA+2.75%
Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 millionPUBT·Jun 22 at 07:18 PMSVRA+2.75%
Savara Announces New Employment Inducement Grant | SVRA Stock NewsStockTitan·Jun 12 at 07:05 AMSVRA+2.75%
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock NewsStockTitan·May 19 at 11:15 PMSVRA+2.75%IBB-0.57%
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock NewsStockTitan·May 19 at 05:15 AMSVRA+2.75%XBI+0.87%
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock NewsStockTitan·May 18 at 05:55 AMSVRA+2.75%
